Get the Stockscreener App
20.37
1.75%
0.35
Pre-market:
20.37
Denali Therapeutics Inc stock is traded at $20.37, with a volume of 1.23M.
It is up +1.75% in the last 24 hours and down -4.28% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
See More
Previous Close:
$20.02
Open:
$20.29
24h Volume:
1.23M
Relative Volume:
0.75
Market Cap:
$3.18B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-7.1474
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-8.61%
1M Performance:
-4.28%
6M Performance:
+37.73%
1Y Performance:
+27.71%
1-Day Range:
$19.94
$20.92
1-Week Range:
$19.76
$22.39
52-Week Range:
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.37 | 3.13B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
DNLI: Pivotal 2026 ahead with FDA review, new launches, and major clinical milestones in rare diseases - TradingView
Fisher Asset Management LLC Increases Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Wider Losses And New Shelf Registration - Sahm
Denali Therapeutics Inc. (DNLI) Investor Outlook: Analyzing The 56.80% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 182,183 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Jefferies reiterates Denali stock Buy rating on gene therapy outlook By Investing.com - Investing.com India
Jefferies reiterates Denali stock Buy rating on gene therapy outlook - Investing.com
BTIG Research Increases Denali Therapeutics (NASDAQ:DNLI) Price Target to $36.00 - MarketBeat
Denali Therapeutics Inc. Trade Ideas — GETTEX:4DN - TradingView
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - National Today
DNLI Should I Buy - Intellectia AI
Does Denali Therapeutics' (DNLI) Widening Quarterly Loss Reframe Its Pipeline-First Investment Narrative? - simplywall.st
Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Denali Therapeutics Q4 net loss deepens - TradingView
Denali Therapeutics (DNLI) widens 2025 loss but fortifies cash for key 2026 drug milestones - Stock Titan
Hunter syndrome drug nears April FDA call as Denali raises $475M - Stock Titan
Volume Recap: Is Denali Therapeutics Inc. a turnaround storyMarket Weekly Review & Weekly Chart Analysis and Guides - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Strong Buy Ratings Signal a 57% Potential Upside - DirectorsTalk Interviews
Wolfe Research initiates Denali Therapeutics stock with Peerperform - Investing.com
Wolfe Research initiates Denali Therapeutics stock with Peerperform By Investing.com - Investing.com UK
Wolfe Research Initiates Coverage of Denali Therapeutics (DNLI) with Peer Perform Recommendation - Nasdaq
(DNLI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Buyout Rumor: Is Denali Therapeutics Inc forming a bullish divergenceJuly 2025 Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Action: Will ORKA stock recover after earningsInsider Selling & Weekly Setup with ROI Potential - baoquankhu1.vn
Aberdeen Group plc Buys 210,835 Shares of Denali Therapeutics Inc. $DNLI - Defense World
Denali Therapeutics (DNLI) Expected to Announce Earnings on Thursday - MarketBeat
Denali Therapeutics Inc. $DNLI Shares Sold by Thrivent Financial for Lutherans - Defense World
Pharma could be on the cusp of finally breaking the blood-brain barrier - Pharma Voice
Big Picture: Why is Denali Therapeutics Inc stock going downJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
How Denali Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - mfd.ru
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
(DNLI) Risk Channels and Responsive Allocation - Stock Traders Daily
Ideas Watch: Is Denali Therapeutics Inc. a turnaround storyEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Denali Therapeutics (DNLI) Valuation After WORLDSymposium Clinical Updates And Regulatory Progress - Sahm
Principal Financial Group Inc. Purchases 198,207 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Gets a Buy from Wedbush - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
Published on: 2026-02-08 06:47:50 - baoquankhu1.vn
Denali Therapeutics (NASDAQ:DNLI) Earns Buy Rating from BTIG Research - MarketBeat
Earnings Recap: Is Denali Therapeutics Inc forming a bullish divergenceBull Run & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - The Manila Times
Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop - MarketBeat
DNLI: Sustained biomarker normalization and clinical gains achieved in Hunter syndrome and MPS IIIA - TradingView
Denali Therapeutics Reports Promising Clinical Trial Data for Tividenofusp Alfa and Other Enzyme Replacement Therapies in Lysosomal Storage Disorders - Quiver Quantitative
Trial data track Denali enzyme drugs for rare brain and muscle diseases - Stock Titan
A Look At Denali Therapeutics (DNLI) Valuation As New ETV Rare Disease Data Presentations Approach - Yahoo Finance
How Denali’s Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors - Yahoo Finance
Denali Therapeutics Inc. (DNLI): Investor Outlook Reveals 44.49% Potential Upside In Neurodegenerative Drug Development - DirectorsTalk Interviews
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Is Denali Therapeutics Inc stock suitable for long term investingJuly 2025 Sentiment & Weekly High Conviction Ideas - baoquankhu1.vn
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):